- Home
- FGF vs NXTC Comparison
FGF vs NXTC Comparison
Compare FGF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- NXTC
- Stock Information
- Founded
- FGF 2012
- NXTC 2015
- Country
- FGF United States
- NXTC United States
- Employees
- FGF N/A
- NXTC N/A
- Industry
- FGF Property-Casualty Insurers
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- FGF Finance
- NXTC Health Care
- Exchange
- FGF Nasdaq
- NXTC Nasdaq
- Market Cap
- FGF 28.0M
- NXTC 31.6M
- IPO Year
- FGF N/A
- NXTC 2019
- Fundamental
- Price
- FGF $22.01
- NXTC $0.89
- Analyst Decision
- FGF
- NXTC Strong Buy
- Analyst Count
- FGF 0
- NXTC 2
- Target Price
- FGF N/A
- NXTC $4.00
- AVG Volume (30 Days)
- FGF 35.7K
- NXTC 218.5K
- Earning Date
- FGF 11-14-2024
- NXTC 11-07-2024
- Dividend Yield
- FGF N/A
- NXTC N/A
- EPS Growth
- FGF N/A
- NXTC N/A
- EPS
- FGF N/A
- NXTC N/A
- Revenue
- FGF $22,351,000.00
- NXTC N/A
- Revenue This Year
- FGF N/A
- NXTC N/A
- Revenue Next Year
- FGF N/A
- NXTC N/A
- P/E Ratio
- FGF N/A
- NXTC N/A
- Revenue Growth
- FGF N/A
- NXTC N/A
- 52 Week Low
- FGF $14.21
- NXTC $0.87
- 52 Week High
- FGF $40.75
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- FGF 38.52
- NXTC 22.88
- Support Level
- FGF $23.48
- NXTC $1.06
- Resistance Level
- FGF $27.00
- NXTC $1.21
- Average True Range (ATR)
- FGF 3.44
- NXTC 0.10
- MACD
- FGF -1.21
- NXTC -0.02
- Stochastic Oscillator
- FGF 1.32
- NXTC 5.21
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segment includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.